logo

For the Inventor, By the Inventor

Salt Lake City, UT, United States of America

Arrien Pharmaceuticals LLC

USPTO Granted Patents = 14


Forward Citations = 32

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Hariprasad Vankayalapati (14 out of 51 patents)

silverMedal Venkatakrishnareddy Yerramreddy (9 out of 9 patents)

bronzeMedal Rajendra P Appalaneni (9 out of 9 patents)

4.  Y Venkata Krishna Reddy (3 out of 3 patents)

5.  Venu Babu Ganipisetty (3 out of 3 patents)

6.  Sureshkumar Talluri (3 out of 3 patents)

7.  Paramareddy Gangireddy (2 out of 2 patents)

8.  Y Vekata Krishna Reddy (1 out of 1 patent)


14 patents:

1. 11053221 - Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity (2021-07-06),
2. 10682358 - Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2020-06-16),
3. 10172866 - Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2019-01-08),
4. 9962382 - Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors (2018-05-08),
5. 9951062 - Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2018-04-24),
6. 9890153 - Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2018-02-13),
7. 9834551 - Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors (2017-12-05),
8. 9669028 - [object Object] (2017-06-06),
9. 9446047 - Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis (2016-09-20),
10. 9359315 - [object Object] (2016-06-07),
11. 9260426 - Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors (2016-02-16),
12. 9206188 - [object Object] (2015-12-08),
13. 9187473 - [object Object] (2015-11-17),
14. 8791112 - [object Object] (2014-07-29),
Company Overview
Arrien Pharmaceuticals LLC, based in Salt Lake City, UT, is dedicated to advancing innovative therapies in the field of pharmaceuticals. The company specializes in the development of novel drug candidates aimed at addressing unmet medical needs across various therapeutic areas. With a focus on research and development, Arrien Pharmaceuticals leverages cutting-edge technology and scientific expertise to create effective solutions that enhance patient care and improve health outcomes. Their commitment to innovation positions them as a key player in the pharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#100 in Salt Lake City, UT

#263 in Utah

#22,333 in US

#42,290 in the World

Salt Lake City, UT (US)
Salt Lake City, UT, United States of America

Arrien Pharmaceuticals LLC

Forward Citations = 32

8 inventors:

goldMedal Hariprasad Vankayalapati (14 out of 51 patents)

silverMedal Venkatakrishnareddy Yerramreddy (9 out of 9 patents)

bronzeMedal Rajendra P Appalaneni (9 out of 9 patents)

4.  Y Venkata Krishna Reddy (3 out of 3 patents)

5.  Venu Babu Ganipisetty (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arrien Pharmaceuticals LLC. Retrieved from https://idiyas.com/company/arrien-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…